UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 10-QSB

         [X] QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
             ACT OF 1934

         For the quarterly period ended              AUGUST 31, 2003
                                                     ---------------

         Commission File Number                      0-12305
                                                     -------


                             REPRO-MED SYSTEMS, INC.
                             -----------------------
             (Exact name of registrant as specified in its charter)


               NEW YORK                                   13-3044880
               --------                                   ----------
     (State or other jurisdiction of                     (IRS Employer
     incorporation or organization)                    Identification No.)


         24 CARPENTER ROAD, CHESTER, NY                      10918
         ------------------------------                      -----
     (Address of principal executive offices)              (Zip Code)


Registrant's telephone number, including area code   (845) 469-2042
                                                     --------------

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act during the
past 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the
past 90 days.  Yes ( X )   No (   )

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

                  Class                       Outstanding at Aug. 31, 2003
                  -----                       ----------------------------
       COMMON STOCK, $.01 PAR VALUE                23,504,000 SHARES

<PAGE>
                             Repro-Med Systems, Inc.
                                Table of Contents


Part I                                                                      PAGE
                                                                            ----
Item 1.  Financial Statements
         Balance Sheet (Unaudited) - August 31, 2003 and
         February 28, 2003 (Audited) ..........................................3

         Statements of Operations (Unaudited) - for the three-months and
         six months ending August 31, 2003 and August 31, 2002 ................4

         Statements of Cash Flow (Unaudited) - for the six months
         ending August 31, 2003 and 2002 ......................................5

         Notes to Unaudited Financial Statements ..............................6

Item 2.  Management's Discussion and Analysis of
         Financial Condition and Results of Operations ........................7

PART II

Item 1.  Legal Proceedings ....................................................9

Item 2.  Changes in Securities ................................................9

Item 3.  Defaults Upon Senior Securities ......................................9

Item 4.  Submission of Matters to a Vote of Security Holders ..................9

Item 5.  Other Information ...................................................10

Item 6.  Exhibits and Reports on Form 8-K ....................................10


                                        2
<PAGE>
                             REPRO-MED SYSTEMS, INC.
                                  BALANCE SHEET
                                    UNAUDITED

                                                      August 31,    February 28,
                                                        2003            2003
ASSETS                                               (Unaudited)     (Audited)
CURRENT ASSETS                                       -----------    -----------
    Cash & Cash Equivalents ......................   $    38,623         16,738
    Accounts Receivable, net .....................       198,166        184,103
    Inventory ....................................       389,584        381,623
    Prepaid Expenses & Other Receivables .........        16,673         11,470
                                                     -----------    -----------
TOTAL CURRENT ASSETS .............................       643,046        593,934
                                                     -----------    -----------
EQUIPMENT & OTHER ASSETS
    Total Equipment ..............................     1,204,682      1,199,772
    Less - Accumulated Depreciation ..............      (820,775)      (784,017)
                                                     -----------    -----------
    Net Book Value of Equipment ..................       383,907        415,755
    Deposits .....................................        31,302         54,802
    Other Assets .................................        48,392         46,135
                                                     -----------    -----------
TOTAL EQUIPMENT & OTHER ASSETS ...................       463,601        516,692
                                                     -----------    -----------
TOTAL ASSETS .....................................   $ 1,106,647    $ 1,110,626
                                                     ===========    ===========
LIABILITIES & STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
    Accounts Payable .............................   $   317,510        267,634
    Notes Payable to Related Parties .............       125,000         84,000
    Accrued Expenses .............................        68,982         66,543
    Accrued Salaries and Wages ...................        33,962             --
    Bank Line of Credit Payable ..................       199,461        199,461
    Current Portion of Leases Payable ............        27,357         26,492
    Current Portion Capital Gain .................        22,481         22,481
                                                     -----------    -----------
    Total Current Liabilities ....................       794,753        666,611
                                                     -----------    -----------
OTHER LIABILITIES
    Long-Term Portion of Leases Payable ..........        29,114         45,614
    Deferred Capital Gain Income .................       325,975        337,215
                                                     -----------    -----------
TOTAL LIABILITIES ................................     1,149,842      1,049,440
                                                     -----------    -----------
STOCKHOLDERS' EQUITY
    Preferred Stock, 8% Cumulative $.01
    Par Value Authorized 2,000,000 Issued &
    Outstanding 10,000 Shares
      (liquidation value $100,000) ...............           100            100
    Common Stock, $.01 Par Value,
    Authorized 50,000,000 Shares, Issued &
    Outstanding 23,504,000(Includes 2,275,000
      of Treasury Shares) Respectively ...........       235,040        235,040
    Additional Paid-in Capital ...................     2,211,631      2,211,631
    Accumulated Deficit ..........................    (2,347,966)    (2,243,585)
    Treasury Stock at Cost .......................      (142,000)      (142,000)
                                                     -----------    -----------
TOTAL STOCKHOLDERS' EQUITY .......................       (43,195)        61,186
                                                     -----------    -----------
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY .........   $ 1,106,647    $ 1,110,626
                                                     ===========    ===========

            See Accompanying Notes to Unaudited Financial Statements

                                        3
<PAGE>
<TABLE>
                                   REPRO-MED SYSTEMS, INC.
                                  STATEMENTS OF OPERATIONS
                                          UNAUDITED
<CAPTION>

                                   FOR THE 3 MONTHS ENDED        FOR THE 6 MONTHS ENDED
                                 AUG 31, 2003   AUG 31, 2002   AUG 31, 2003   AUG 31, 2002
                                 ------------   ------------   ------------   ------------
<S>                              <C>            <C>            <C>            <C>
SALES

Net Sales of Products .........  $    379,694   $    451,840   $    809,195   $    887,082

COST AND EXPENSES

  Cost of Goods Sold ..........       181,427        303,953        380,072        621,218
  Selling, General &
     Administrative Expenses ..       230,503        134,509        452,442        273,071
  Research and Development ....        11,757          5,378         20,437         10,791
  Depreciation and Amortization        20,077         19,913         39,811         41,501
                                 ------------   ------------   ------------   ------------
TOTAL COST AND EXPENSES .......       443,764        463,753        892,762        946,581
                                 ------------   ------------   ------------   ------------


(LOSS) FROM OPERATIONS ........       (64,070)       (11,913)       (83,567)       (59,499)

Non-Operating Income (Expense)
  Interest (Expense) ..........        (7,581)        (6,329)       (16,378)       (13,321)
  Interest & Other Income .....           158            358            395          5,461
                                 ------------   ------------   ------------   ------------
                                       (7,423)        (5,971)       (15,983)        (7,860)
                                 ------------   ------------   ------------   ------------


(LOSS) BEFORE INCOME TAXES ....       (71,493)       (17,884)       (99,550)       (67,359)

  Provision for Income Taxes ..             0              0           (831)          (702)
                                 ------------   ------------   ------------   ------------
NET (LOSS) AFTER TAXES ........       (71,493)       (17,884)      (100,381)       (68,061)
                                 ============   ============   ============   ============
(LOSS) PER COMMON SHARE

  Primary .....................        ($0.01)        ($0.01)        ($0.01)        ($0.01)
  Fully Diluted ...............        ($0.01)        ($0.01)        ($0.01)        ($0.01)

Average Common Shares
  Outstanding .................    23,504,000     23,504,000     23,504,000     23,504,000


                       See Accompanying Notes to Financial Statements

                                              4
</TABLE>
<PAGE>
                             REPRO-MED SYSTEMS, INC.
                            STATEMENTS OF CASH FLOWS
                            FOR THE SIX MONTHS ENDED
                                    UNAUDITED

                                                         AUGUST 31,   AUGUST 31,
                                                           2003         2002
                                                         ---------    ---------
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) ...........................................   ($100,381)    ($68,061)
Adjustments to reconcile net (loss) to cash
 (used) in operating activities:
  Depreciation and Amortization ......................      39,811       41,501
  Capital Gain - Building Lease ......................     (11,240)     (11,240)
  Decrease (Increase) in Accounts Receivable .........     (14,063)      59,505
  Decrease (Increase) in Inventory ...................      (7,961)      57,019
  (Decrease) Increase in Accrued Salaries
     and Wages .......................................      33,962
  Increase in Prepaid Expenses .......................      (5,203)     (18,491)
  (Decrease) Increase in Accounts Payable ............      49,876       35,599
  (Decrease) Increase in Accrued Expenses ............       2,439      (26,295)
                                                         ---------    ---------

NET CASH PROVIDED BY (USED IN) OPERATIONS ............     (12,760)      69,537
                                                         ---------    ---------
CASH FLOWS FROM INVESTING ACTIVITIES
  Decrease in Security Deposit .......................      23,500            -
  Capital Expenditures ...............................     (10,220)     (21,968)
                                                         ---------    ---------
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES ......      13,280      (21,968)
                                                         ---------    ---------

CASH FLOW PROVIDED BY FINANCING ACTIVITIES
  Increase in Notes Payable to Related Parties .......      41,000       15,000
  Preferred Stock Dividend ...........................      (4,000)      (4,000)
  Payments, Increased Obligations on
     Capitalized Leases ..............................     (15,635)       4,546
                                                         ---------    ---------

CASH FLOW PROVIDED BY FINANCING ACTIVITIES ...........      21,365       15,546
                                                         ---------    ---------

NET INCREASE IN CASH .................................      21,885       63,115

Cash and Cash Equivalents, beginning of period .......      16,738       25,670
Cash and Cash Equivalents, end of period .............   $  38,623    $  88,785


SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
  Interest ...........................................      16,378       13,321
                                                         ---------    ---------
  Income Taxes .......................................         831          702
                                                         =========    =========

                 See Accompanying Notes to Financial Statements

                                       5
<PAGE>

REPRO-MED SYSTEMS, INC.
NOTES TO THE FINANCIAL STATEMENTS

BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
statements and with instructions to Form 10-QSB. Accordingly, they do not
include all of the information and disclosures required for annual financial
statements. These financial statements should be read in conjunction with the
financial statements and related footnotes for the year ended February 28, 2003
included in the Form 10-KSB for the year then ended.

As shown in the accompanying interim financial statements, the Company incurred
a net loss of $100,381 during the six months ended August 31, 2003 and has a
negative equity position of $43,195 at August 31, 2003. The Company seeks to
raise additional capital or financing, to improve their liquidity. These factors
create substantial doubt as to the Company's ability to continue as a going
concern. These financial statements do not include any adjustments to the
financial statements that might be necessary should the Company be unable to
continue as a going concern.

In the opinion of the Company's management, all adjustments (consisting of
normal recurring accruals) necessary to present fairly the Company's financial
position as of August 31, 2003, and the results of operations and cash flows for
the six month periods ended August 31, 2003 and 2002 have been included.

The results of operations for the six-month period ended August 31, 2003, are
not necessarily indicative of the results to be expected for the full year. For
further information, refer to the financial statements and footnotes thereto
included in the Company's Form 10-KSB as filed with the Securities and Exchange
Commission for the year ended February 28, 2003.

In March, 2003, the Company negotiated with the landlord of its Chester, New
York, facility to utilize $27,500 of its security deposit (held by the landlord)
to pay March and April, 2003, rent. The agreement provides for replenishment
within 90 days. At the date of this filing, the security deposit had not been
repaid.

SHORT-TERM FINANCING

As of August 31, 2003, the Company had an outstanding balance of $199,461 on its
bank line of credit. The line agreement officially ended on June 30, 2001 but
was verbally renewed by the bank through June 30, 2003. The loan is currently
due.

LOAN PROGRAM WITH OFFICERS, DIRECTORS AND OTHERS

In April, 2003, the Company offered its officers, directors, employees and
others the opportunity to lend the company funds at the rate of 2% over the
prime rate charged by the Company's principal bank on the last day of each
quarter which is payable quarterly. Additionally, the Company will grant one
share of common stock per quarter for each dollar of principal indebtedness on
the unpaid principal balance. At June 30, 2003, $25,000 was outstanding under
the loan agreements. Accordingly, the Company is obligated to issue 25,000
shares having a market value of $1,250 and record stock-based compensation. The
shares due at the date of this report had not been issued, but the stock-based
compensation has been recorded.

                                       6
<PAGE>

PART I ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS

This Quarterly Report on Form 10-QSB contains certain "forward-looking"
statements (as such term is defined in the Private Securities Litigation Reform
Act of 1995) and information relating to us that are based on the beliefs of the
management, as well as assumptions made by and information currently available.
Our actual results may vary materially from the forward-looking statements made
in this report due to important factors such as, recent operating losses,
uncertainties associated with future operating results, unpredictability related
to Food and Drug Administration regulations, introduction of competitive
products, limited liquidity, reimbursement related risks, government regulation
of the home health care industry, success of the research and development
effort, market acceptance of FREEDOM60, availability of sufficient capital to
continue operations and dependence on key personnel. When used in this report,
the words "estimate," "project," "believe," "anticipate," "intend," "expect" and
similar expressions are intended to identify forward-looking statements. Such
statements reflect current views with respect to future events based on
currently available information and are subject to risks and uncertainties that
could cause actual results to differ materially from those contemplated in such
forward-looking statements. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. These
statements involve risks and uncertainties with respect to the ability to raise
capital to develop and market new products, acceptance in the market place of
new and existing products, ability to penetrate new markets, our success in
enforcing and obtaining patents, obtaining required Government approvals and
attracting and maintaining key personnel that could cause the actual results to
differ materially. Repro-Med does not undertake any obligation to release
publicly any revision to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

THREE MONTHS ENDED AUGUST 31, 2003 VS. 2002

Sales of products in the Freedom60 line increased 4.7% quarter over quarter
ended August 31, 2003. The softening of world economic markets and pressure on
domestic municipal budgets continued to affect purchases of Res-Q-Vac, with
sales decreasing 29.5% quarter over quarter. The decrease in Res-Q-Vac and
non-core product sales was partially offset by a $38,200 increase in OEM sales.
Overall, net sales decreased 16% overall to $379,694 (2003) from $451,840 (2002)
for the quarter.

Gross profit increased to 52% of net sales in 2003 from 33% in 2002 primarily
due to improvements in production efficiencies and reallocation of certain
expenses to more accurately reflect actual production costs.

Selling, general and administrative expense increased by $95,994 in 2003 from
$134,509 in 2002 primarily as the result of these same reallocations and an
increase in sales and marketing expenditures.

Research and development expenses increased $6,379 from 2002 to 2003, again as a
result of cost reallocations.

Depreciation and amortization expenses increased slightly during this period
reflecting capital equipment purchases and amortization of patent and trademark
costs in 2003.

Interest expense increased 19.8% as a result of an increase in loans by related
parties to the Company and additional capitalized leases.

                                        7
<PAGE>

SIX MONTHS ENDED AUGUST 31, 2002 VS. 2001

Sales of products in the Freedom60 line increased 12.8% for the six-months ended
August 31, 2003 vs. the six-months ended August 31, 2002. Net sales decreased
8.8% overall to $809,195 (2003) from $887,082 (2002) for the six month period,
reflecting lower sales of the Company's other core product, Res-Q-Vac, which
decreased 18.4% in the same six month period. The decrease in Res-Q-Vac and
non-core product sales was partially offset by a $66,600 increase in OEM sales
during the six month period.

Gross profit increased to 53% of net sales in 2003 from 30% in 2002 primarily
due to improvements in production efficiencies and reallocation of certain
expenses to more accurately reflect actual production costs.

Selling, general and administrative expense increased by $179,371 in 2003 from
$273,071 in 2002 primarily as the result of these same reallocations and an
increase in sales and marketing expenditures.

Research and development expenses increased $9,646 from 2002 to 2003, again as a
result of cost reallocations.

Interest expense increased 23% as a result of an increase in loans by related
parties to the Company and additional capitalized leases.

Other income decreased by $5,066 due in large part to refunds received during
FY2003 for expenses from a prior year and which did not recur during the current
fiscal year.

LIQUIDITY AND CAPITAL RESOURCES

During June 2000, we negotiated a $200,000 line of credit with M&T Bank that is
guaranteed by the President and one of the directors. As of August 31, 2003,
$199,461 has been advanced on the line of credit. Although the line expired on
June 30, 2002, the bank verbally extended the line through June 30, 2003. We are
requesting the bank to extend the line for another six months. The bank has
assured the Company that if the line is not renewed, there will be no
requirement for immediate repayment of the line.

We continue to work towards positive cash flow and have several opportunities to
improve sales of our key products, RES-Q-VAC and Freedom60. In March, 2003, we
signed a contract with Joint Purchasing Corporation. JPC is a non-profit, health
services organization headquartered in New York that helps healthcare providers
strengthen their bottom line by assisting in the implementation of cost control
and resource management strategies. JPC has approximately 3,500 members and is
assisting us in promoting our cost saving products to their members.

In April, we signed agreements with an outside salesman to provide field
representation for our products and with a medical consultant who is introducing
us to national distributors and buying groups. As a result of these activities,
an agreement with a national distributor, Sammons Preston Rolyan has been signed
for Freedom60, RES-Q-VAC and our Gyneco products. Also, during the first quarter
an agreement was signed with one of our vendors to license, sell and promote the
Freedom60 as well as securing potential investment in the Company. Sammons has
introduced us to the largest nursing home provide in the United States who
expressed serious interest in our products. We are anticipating agreements with
several additional national and regional distributors and Group Purchasing
Organizations as well as with several independent representatives.

In August we signed an agreement with Pharmed, a minority owned distributor in
the state of Florida, and have trained 17 of their sales staff on the Res-Q-Vac
and Freedon60. Pharmed has begun to open the hospital market for the Res-Q-Vac,
a new market opportunity for this product line. We also completed an agreement
with Trinity Medical Solutions, which services the Veterans Affairs market.

                                       8
<PAGE>

We have trained a new specialty sales group in Freedom60 and plan to begin
training a second group in the near future. During a recent visit with one of
our new health care providers in Knoxville, TN, we were informed that the
continually diminishing reimbursement situation is expected to cause the market
to seek out the Freedom60 to sustain their growth and provide quality medical
care at affordable cost.

In August, we signed an exclusive marketing agreement with International
Products, Inc. (IPI), a Connecticut corporation, for our Gyneco and Masterson
product lines. The agreement provides exclusive world-wide marketing rights to
IPI for the Gyneco products. We believe that the Masterson Endometrial Biopsy
System can be successfully re-introduced into the market with sufficient capital
to reposition the product. IPI is also responsible for marketing the Gyneco
Thermal Cautery System and both Companies are negotiating with several
independent sales groups to access this market.

We are commencing a marketing program for the Res-Q-Vac with our new Full Stop
Protection, which prevents the spread of diseases such as HIV/AIDS, SARS,
hepatitis, tuberculosis, among others. Recently the Centers for Disease Control
(CDC) has recommended the use of adequate protection when dealing with the SARS
virus which is expected to reappear. The filtration capabilities of Full Stop
Protection are also incorporated in the OSHA regulations as a requirement under
their engineering controls. As far as we know, our Res-Q-Vac is the only such
portable suction system to incorporate this technology which is also covered
under U.S Patent #6,575,946. With Full Stop Protection, the cost of each
individual use of Res-Q-Vac is actually reduced since the filter protects the
pump. Competing devices, although less expensive initially, must be disposed of
after use, and thus are more costly per use than Res-Q-Vac. With the limited
resources available, we are promoting these benefits which we believe make the
Res-Q-Vac a desirable and needed product.

Our distributor in Europe, Gama Sanitos, is actively engaged in establishing the
Freedom60 as the device of choice for the treatment of post operative pain
control throughout Europe. We are exploring the potential of this market in
domestic market. Gama Sanitos is also jointly developing a variable rate flow
controller with us which will enhance the operation of the Freedom60 as well as
have uses on other pressurized pump systems, as well as providing support for
Freedom60 in the chemotherapy market.

We continue to pursue capital investment through debt or equity to increase our
marketing and sales, and to enhance our existing products as well as new line
additions.

PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

The Company is neither a party to any material litigation, nor to the knowledge
of the officers and directors of the Company, is there any material litigation
threatened against the Company.

ITEM 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS

None

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders of the Company during
the quarter ended August 31, 2003.

                                       9
<PAGE>

ITEM 5.  OTHER INFORMATION

None

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

31.1     Certification of Chief Executive Officer and Principal Financial
         Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1     Certification of Chief Executive Officer and Principal Financial
         Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(b) Reports of Form 8-K

Form 8-K/A, Item 4, Changes in Registrant's Certifying Accountant, incorporated
by reference dated February 28, 2003, as amended July 14, 2003.



                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934 the Registrant has duly caused this report to be signed on its
behalf by the undersigned; thereunto duly authorized.

REPRO-MED SYSTEMS, INC.

/s/ Andrew I. Sealfon                                         October 20, 2003
---------------------
Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, and
Chief Executive Officer



                                       10